Loading...

Brilliant Violet 711™ anti-mouse CD64 (FcγRI) Antibody

Pricing & Availability
Clone
X54-5/7.1 (See other available formats)
Regulatory Status
RUO
Other Names
FcRI
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
X54-57.1_BV711_CD64_Antibody_FC_1_061714.jpg
C57BL/6 mouse bone marrow cells were stained with CD11b FITC and CD64 (clone X54-5/7.1) Brilliant Violet 711™ (top) or mouse IgG1, κ Brilliant Violet 711™ isotype control (bottom). Data shown was gated on myeloid cells.
  • X54-57.1_BV711_CD64_Antibody_FC_1_061714.jpg
    C57BL/6 mouse bone marrow cells were stained with CD11b FITC and CD64 (clone X54-5/7.1) Brilliant Violet 711™ (top) or mouse IgG1, κ Brilliant Violet 711™ isotype control (bottom). Data shown was gated on myeloid cells.
  • X54-57.1_BV711_CD64_Antibody_FC_2_061714.jpg
Compare all formats See Brilliant Violet 711™ spectral data
Cat # Size Price Quantity Check Availability Save
139311 50 µg 292 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD64 is a 72 kD single chain type I glycoprotein also known as FcγRI and FcRI. CD64 is a member of the immunoglobulin superfamily and is expressed on monocytes/macrophages, dendritic cells, and mast cells. The expression can be upregulated by IFN-γ stimulation. CD64 binds IgG immune complex. It plays a role in antigen capture, phagocytosis of IgG/antigen complexes, and antibody-dependent cellular cytotoxicity (ADCC).

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
BALB/c mouse FcγRI-human IgG Fc fusion protein.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The X54-5/7.1 antibody reacts with mouse strains carrying CD64a and b alleles but not CD64d. X54-5/7.1 recognizes a conformational determinant formed between domains 2 and 3. Additional reported application (for relevant formats) include: immunoprecipitation1, and spatial biology (IBEX)5,6. Clone X54-5/7.1 is not found to be useful for Western blots1.

Application References

(PubMed link indicates BioLegend citation)
  1. Tan PS, et al. 2003. J. Immunol. 170:2549. (IP)
  2. Ingersoll MA, et al. 2010. Blood 115:e10. (FC)
  3. Ozeri E, et al. 2012. J. Immunol. 189:146. PubMed
  4. Richardson ML, et al. 2014. PLoS Negl Trop Dis. 8:2825. PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
  2. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  3. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  4. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  5. Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed
  6. Siret C, et al. 2022. Nat Commun. 13:7366. PubMed
  7. Solier S, et al. 2023. Int J Mol Sci. 24:. PubMed
  8. Harpur CM, et al. 2023. Clin Transl Immunology. 12:e1443. PubMed
  9. Wang KC, et al. 2018. Immunohorizons. 2:407. PubMed
  10. Scott CL et al. 2018. Immunity. 49(2):312-325 . PubMed
  11. Shmuel-Galia L, et al. 2021. Immunity. 54(6):1137-1153.e8. PubMed
  12. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  13. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  14. Bauché D et al. 2018. Immunity. 49(2):342-352 . PubMed
  15. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  16. Di Gioia M, et al. 2020. Nat Immunol. 21:42. PubMed
  17. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  18. Xu M et al. 2018. Immunity. 48(4):787-798 . PubMed
  19. Devos M, et al. 2020. J Exp Med. 217:00:00. PubMed
  20. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  21. Benechet AP, et al. 2019. Nature. 574:200. PubMed
  22. Hartwig T et al. 2018. Cell reports. 25(13):3564-3572 . PubMed
  23. Lin J, et al. 2017. Sci Rep. 7:41722. PubMed
  24. Bonnardel J, et al. 2019. Immunity. 51:638. PubMed
  25. Cho YK, et al. 2022. Nat Commun. 13:4084. PubMed
  26. Goossens P, et al. 2019. Cell Metab. 29:1376. PubMed
  27. Yang C, et al. 2021. J Invest Dermatol. 810:141. PubMed
  28. Tondini E, et al. 2022. NPJ Vaccines. 7:64. PubMed
  29. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  30. Prooyen N, et al. 2016. PLoS One. 12: 1005749. PubMed
  31. de Reuver R, et al. 2021. Cell Reports. 36(6):109500. PubMed
  32. De Simone G, et al. 2021. Immunity. :. PubMed
  33. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  34. Blriot C, et al. 2021. Immunity. :. PubMed
  35. Guilliams M, et al. 2022. Cell. 185:379. PubMed
  36. Gentek R, et al. 2018. Immunity. 48:1160. PubMed
  37. Etzerodt A, et al. 2019. J Exp Med. 216:2394. PubMed
  38. Wuggenig P, et al. 2020. Commun Biol. 3:130. PubMed
  39. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  40. Bellomo A, et al. 2020. Immunity. 53(1):127-142.e7. PubMed
  41. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  42. Cordeiro B, et al. 2020. Cell Reports. 31(5):107585. PubMed
  43. Bosteels C, et al. 2020. Immunity. 52(6):1039-1056.e9.. PubMed
  44. Mogilenko DA et al. 2019. Cell. 177(5):1201-1216 . PubMed
  45. Van Nuffel E, et al. 2020. EMBO Rep. 21:e49237. PubMed
  46. Scheraga RG, et al. 2020. J Immunol. 1310:204. PubMed
  47. Catrysse L, et al. 2021. Cell Rep. 36:109748. PubMed
  48. Filtjens J, et al. 2021. Nat Commun. 12:2936. PubMed
  49. Goldberg MF et al. 2018. Immunity. 49(6):1090-1102 . PubMed
  50. Buschor S, et al. 2017. PLoS Pathogens. 13(6):e1006476. PubMed
  51. Etzerodt A, et al. 2020. J Exp Med. 217:00:00. PubMed
RRID
AB_2563846 (BioLegend Cat. No. 139311)

Antigen Details

Structure
Ig superfamily, type I glycoprotein, 72 kD
Distribution

Monocytes, macrophages, mast cells, dendritic cells

Function
Phagocytosis, ADCC
Ligand/Receptor
IgG
Cell Type
Dendritic cells, Macrophages, Mast cells, Monocytes
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, Fc Receptors
Gene ID
14129 View all products for this Gene ID
UniProt
View information about CD64 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 12.14.2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account